Galvus (vildagliptin) - DPP-IV Inhibitor / Oral Antidiabetic Agent

Current estimates indicate that worldwide about 170 million people suffer from diabetes, which is projected to reach 366 million by 2030.

| 1 | 2 | 3 | 4 | 5 |